Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Lands $2.2M DoD Contract for Array-based Biothreat Dx

NEW YORK (GenomeWeb News) - The US Department of Defense has awarded CombiMatrix a one-year, $2.2 million contract to continue developing its microarrays to detect pathogens and toxins for use in bio-terror defense, CombiMatrix said today.
The company said under earlier DoD-funded programs it “demonstrated that its products can “simultaneously detect toxins, viruses, and bacteria using its semiconductor-based microarrays.”
In October 2006, CombiMatrix won two million-dollar allocations under the 2007 Defense Appropriations Bill to develop these technologies, including a micoarray for the H5N1 avian influenza virus.
Last May, the company won a sub-contract for an undisclosed sum from Northrup Grummon to help develop a handheld sensor to detect bio-threats for the Defense Advanced Research Projects Agency.
The company is designing products to address biothreat agents as well as infectious diseases “of public-health concern,” including influenza A and the avian flu subtype David Danley, director of homeland security and defense programs at CombiMatrix, said in a statement.
The company added that its devices using its electrochemical-based detection systems are already being used “at several military and government laboratories as well as civilian installations.”
CombiMatrix CEO Amit Kumar said the DoD contract “fits nicely with our strategy of developing products for the molecular-diagnostics and the personalized-medicine market segments.”

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.